Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HIF-2-dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear Cell Renal Cell Carcinoma [RNA-seq]

ABSTRACT: Hypercalcemia (HC) in renal cell carcinoma (RCC) patients is associated with reduced survival. HC often involves PTHrP. PTHrP is induced by hypoxia, but whether HIF-2 plays a role in HC is unknown. Here we show that HC is reproduced by transplanting patient tumors (tumorgrafts, TG) in mice resulting in functional deterioration, weight loss, calcium deposition and organ damage. Treatment with PT2399, a specific HIF-2 inhibitor, rapidly normalized calcium levels, downregulated PTHrP and reduced HIF-2 binding to the PTHLH promoter. Interestingly, while the PTHLH locus was generally more accessible in TG(HC), PT2399 did not grossly affect chromatin accessibility, which was consistent with genome-wide studies where promoter accessibility was only reduced in a minority of PT2399-downregulated genes. As in TGs, paraneoplastic HC in humans was associated with clear cell histology and sarcomatoid/rhabdoid differentiation. Interestingly, HC (and PTHrP) was swiftly corrected by the related PT2977/belzutifan drug in a prospective patient with sarcomatoid ccRCC. Our data supports the evaluation of HIF-2 antagonists for ccRCC patients with humoral hypercalcemia of malignancy, which may serve as a predictive biomarker of response (along with PTHrP reduction).

ORGANISM(S): Homo sapiens

PROVIDER: GSE308449 | GEO | 2025/10/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

HIF-2-dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear Cell Renal Cell Carcinoma [ATAC-seq]

Project description:Hypercalcemia (HC) in renal cell carcinoma (RCC) patients is associated with reduced survival. HC often involves PTHrP. PTHrP is induced by hypoxia, but whether HIF-2 plays a role in HC is unknown. Here we show that HC is reproduced by transplanting patient tumors (tumorgrafts, TG) in mice resulting in functional deterioration, weight loss, calcium deposition and organ damage. Treatment with PT2399, a specific HIF-2 inhibitor, rapidly normalized calcium levels, downregulated PTHrP and reduced HIF-2 binding to the PTHLH promoter. Interestingly, while the PTHLH locus was generally more accessible in TG(HC), PT2399 did not grossly affect chromatin accessibility, which was consistent with genome-wide studies where promoter accessibility was only reduced in a minority of PT2399-downregulated genes. As in TGs, paraneoplastic HC in humans was associated with clear cell histology and sarcomatoid/rhabdoid differentiation. Interestingly, HC (and PTHrP) was swiftly corrected by the related PT2977/belzutifan drug in a prospective patient with sarcomatoid ccRCC. Our data supports the evaluation of HIF-2 antagonists for ccRCC patients with humoral hypercalcemia of malignancy, which may serve as a predictive biomarker of response (along with PTHrP reduction).

2025-10-07 | GSE308450 | GEO

HIF2-driven PTHrP Mediates Cachexia and Hypercalcemia in Renal Cell Carcinoma: Successful Treatment with HIF2 Inhibitors [polysome-seq]

Project description:Kidney cancer frequently causes paraneoplastic syndromes, including hypercalcemia and cachexia, but the underlying mechanisms are incompletely understood. The most common form of kidney cancer, clear cell renal cell carcinoma, is frequently caused by loss of the pVHL tumor suppressor protein and the resulting upregulation of the HIF2 transcription factor. We show that PTHLH, which resides on a ccRCC amplicon on chromosome 12p, is a direct HIF2 transcriptional target in ccRCC. Further, we show that the increased PTHLH expression is both necessary and sufficient for the induction of hypercalcemia and cachexia in preclinical orthotopic cell line tumor models. Consistent with these observations, two different allosteric HIF2 inhibitors, belzutifan and NK-2152, rapidly ameliorated hypercalcemia and cachexia in ccRCC patients, including in patients who did not exhibit objective tumor shrinkage.

2025-09-19 | GSE289581 | GEO

HIF2-driven PTHrP Mediates Cachexia and Hypercalcemia in Renal Cell Carcinoma: Successful Treatment with HIF2 Inhibitors

2025-09-19 | GSE289579 | GEO

HIF2-driven PTHrP Mediates Cachexia and Hypercalcemia in Renal Cell Carcinoma: Successful Treatment with HIF2 Inhibitors

2025-02-21 | MSV000097181 | MassIVE

To identify genes responsive to treatment with the HIF2a inhibitor PT2399

Project description:HIF2a function is both necessary and sufficient for the growth of VHL-null clear cell Renal Cell Carcinoma (ccRCC). Targeting HIF2a function can therefore be a promising therapeutic strategy. We used microarray analysis to characterize a novel pharmacological inhibitor of HIF2a named PT2399. By comparing genes that are responsive to PT2399 in parental cells vs cells lacking HIF2a, by virtue of CRISPR-mediated genetic editing, we characterized gene signatures that are regulated by PT2399 in a HIF2a dependent manner. Cells were treated with either DMSO (control) or 2uM PT2399 for indicated time periods, total RNA was extracted and analyzed. Please note that the experiments with 786O Parental and HIF2a null cells were conducted independently.

2016-07-03 | E-GEOD-72959 | biostudies-arrayexpress

Integration of scRNA-seq and scATAC-seq reveals malignant characteristics of clear cell renal cell carcinoma with sarcomatoid differentiation

Project description:Clear cell renal cell carcinoma (ccRCC) is the most common histological type of kidney cancer. The appearance of spindle cell proliferation is generally considered as sarcomatoid differentiation. To further understand the malignant characteristics of this special histological type of ccRCC, it is a promising direction to study it at the level of genetics, cellular and molecular levels. In this study, we integrated scRNA-seq, scATAC-seq and WES analysis on a sample of sarcomatoid ccRCC, and discovered the characteristics of malignant progression. These findings provided a new reference for the diagnosis and treatment of ccRCC with sarcomatoid differentiation in the future.

2025-10-04 | GSE291824 | GEO

Gene expression profiling of clear cell renal cell carcinoma with sarcomatoid transformation

Project description:Renal cell carcinoma (RCC) with sarcomatoid transformation features a biphasic tumour with both sarcomatoid and carcinomatous components. Clear cell RCC (ccRCC) is the most common RCC subtype, frequently exhibits sarcomatoid transformation. The pathogenesis of sarcomatoid ccRCC remains unclear. This study aimed to identify the genes and pathways involved in sarcomatoid ccRCC using gene expression profiling. We analysed three distinct regions including sarcomatoid component, clear cell component and matched normal kidney tissue from formalin-fixed, paraffin-embedded (FFPE) tissue samples of four patients. RNA was extracted and gene expression profiles were analysed using the NanoString nCounter® PanCancer Pathways Panel on the NanoString nCounter® Analysis System. Data analysis was performed using NanoString nSolver™ Analysis Software. Significant gene expression differences were defined with a threshold of fold change ˃ 4 and P-value ˂ 0.05. Compared to normal kidney tissue, 17 genes were significantly different in the clear cell component, with 5 were upregulated and 12 downregulated. The most significantly upregulated and downregulated genes were GDF6 and SFRP1 respectively. In the sarcomatoid component, 85 genes showed differences, with 38 upregulated and 47 downregulated. COL11A1 and LRP2 were the most significantly overexpressed and underexpressed genes respectively. When comparing sarcomatoid component with clear cell component, there were 53 significantly dysregulated genes, including epithelial-mesenchymal transition markers such as MMP9 and FN1. Pathway analysis indicated that PI3K was the most frequently deregulated pathway in the sarcomatoid component, suggesting its role in sarcomatoid transformation. This study provides insights into the gene expression patterns in ccRCC with sarcomatoid transformation.

2025-01-21 | GSE285848 | GEO

To identify genes responsive to treatment with the HIF2a inhibitor PT2399

2016-01-01 | GSE72959 | GEO

HIF-1α and HIF-2α differently regulate tumour development, metabolism and inflammation of clear cell renal cell carcinoma in mice

Project description:Mutational inactivation of VHL is the earliest genetic event in the majority of ccRCCs, leading to activation of the HIF-1α and HIF-2α transcription factors. While correlative studies of human ccRCCs and functional studies using human ccRCC cell lines have implicated HIF-1α as an inhibitor and HIF-2α as a promoter of aggressive tumour behaviours, their roles in tumour onset have not been functionally addressed. Using an autochthonous ccRCC model, we show genetically that Hif1a is necessary for tumour formation whereas Hif2a deletion has only minor effects on tumour initiation and growth. Both HIF-1α and HIF-2α are necessary for the clear cell phenotype. Transcriptomic and proteomic analyses revealed that HIF-1α regulates glycolysis while HIF-2α regulates genes associated with lipoprotein metabolism, ribosome biogenesis and E2F and MYC transcriptional activities. Deficiency of HIF-2α increased CD8+ T cell infiltration and activation. These studies reveal different functions of HIF-1α and HIF-2α in ccRCC. SIGNIFICANCE The roles of HIF-1α and HIF-2α in ccRCC pathogenesis remain unclear. Using a mouse genetic approach we show that HIF-1α but not HIF-2α is important for tumour formation, contrary to predictions from studies of human ccRCC. We show that HIF-1α and HIF-2α transcriptionally regulate different aspects of metabolism and identify HIF-2α as a suppressor of immune cell infiltration and activation.

2020-07-02 | PXD016630 | Pride

Integrative genomic analysis of sporadic clear cell Renal Cell Carcinoma

Project description:Human clear cell renal cell carcinoma (ccRCC) is a common cancer of the kidney. We applied an integrated approach to identify important factors that influence carcinogenesis in ccRCC. 33 frozen ccRCC samples were subject to copy number analysis. The data was analyzed to identify factors affecting tumorigenesis. The samples were also stained for HIF-1alpha and HIF-2alpha expression. The tumors were subtyped based on HIF expression and investigated for differences in genetic aberrations.

2011-12-01 | E-GEOD-27852 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data